Scientists from Germany’s Jülich Research Centre are reporting successful results from the first phase of human clinical testing of a new Alzheimer’s drug.
Following promising animal experiments the drug has initially now proved safe in human subjects and will soon move into Phase II clinical trials testing efficacy.
Called PRI-002, the new drug works by breaking down the toxic amyloid beta protein at the point it is aggregating into oligomer forms.
This article highlights the scope for developing therapeutics with new innovative, alternative approaches. The current trillion dollars pharmaceutical industry is in peril where the current drug development pipeline is slow, inefficient and incapable of being extended to multi-combination drug therapies as well as minimally focused on prevention. The complex modeling of diseases and biological functions has been limited because of the inability to integrate large scale molecular pathways.
Watch this Video to understand how recent advances provide breakthrough technology for doing scalable modeling of complex molecular systems to dramatically accelerate drug discovery and development.